{
    "root": "904931df-ec36-416c-aedd-6a09b1137b57",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": {
        "text": "Lamivudine"
    },
    "value": "20250327",
    "ingredients": [
        {
            "name": "LAMIVUDINE",
            "code": "2T8Q726O95"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "POVIDONE K30",
            "code": "U725QWY32X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ"
        },
        {
            "name": "HYPROMELLOSE 2910 (5 MPA.S)",
            "code": "R75537T0T4"
        }
    ],
    "indications": "Lamivudine is a nucleoside analogue indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. \n                  \n                     Limitations of Use:\n                  \n                  \n                     The      dosage of this product is for HIV-1 and not for HBV.",
    "contraindications": "Adults: 300 mg daily, administered as either 150 mg twice daily or 300 mg once daily. (2.1) Pediatric Patients Aged 3 Months and Older: Administered either once or twice daily. Dose should be calculated on body weight (kg) and should not exceed 300 mg daily. (2.2) Patients with Renal Impairment: Doses of Lamivudine must be adjusted in accordance with renal function. (2.3)",
    "warningsAndPrecautions": "Lamivudine Tablets USP, 150 mg - Scored\n                  \n                  White, circular, biconvex, film coated tablets 'TMT' engraved on one side and breakline on other side.\n                  Bottle of 60 tablets (NDC 64380-710-03) with child-resistant closure.\n                  \n                                 \n                  \n                  \n                     Lamivudine Tablets USP, 300 mg\n                  \n                  White, circular, biconvex, film coated tablets \"L300\" engraved on one side and plain on other side.            \n                  Bottle of 30 tablets (NDC 64380-711-04) with child-resistant closure.\n                              \n                  Recommended Storage:\n                              \n                  Store lamivudine tablets at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from light.",
    "adverseReactions": "Lamivudine Tablets are contraindicated in patients with a previous hypersensitivity reaction to lamivudine."
}